Time Course and Factors Correlating With Ventricular Tachyarrhythmias After Introduction of Steroid Therapy in Cardiac Sarcoidosis.
The time course and factors correlating with ventricular tachyarrhythmias (VTs) after introduction of corticosteroid therapy in patients with cardiac sarcoidosis remain to be elucidated.



We examined 68 consecutive patients with cardiac sarcoidosis in the Tohoku University Hospital from October 1998 to September 2014 (age: 57±11 years old; male:female 18:50) and evaluated VTs after initiation of steroid therapy. VTs were defined as documented ventricular tachycardia or ventricular fibrillation lasting for more than 30 seconds or resulting in cardiovascular collapse, or appropriate implantable cardioverter defibrillator therapy. During a mean follow-up of 5.5 years, 20 out of 68 patients (29%) experienced VTs after initiation of corticosteroid therapy, especially in the first 12 months in 14 patients (70%). A multivariable analysis revealed that positive gallium scintigraphy had a significant correlation with VTs (hazard ratio, 11.33; 95% confidence interval, 3.22-39.92; P<0.001), in addition to reduced left ventricular ejection fraction (hazard ratio, 0.94; 95% confidence interval, 0.90-0.97; P=0.001). Furthermore, electrical storm was noted in 10 patients (14.7%), 8 within the first 12 months of treatment, whereas the recurrence of electric storm was relatively less.



These results indicate that VTs and electric storm frequently occur in the first 12 months after initiation of corticosteroid therapy, presumably because of inflammatory conditions, and that the positive gallium scintigraphy is a significant and independent predictor of VTs. The present findings may be useful to further improve the management of VTs in patients with cardiac sarcoidosis.
From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Masato
M
Segawa
From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan. fukuda@cardio.med.tohoku.ac.jp.
Koji
K
Fukuda
From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Makoto
M
Nakano
From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Masateru
M
Kondo
From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Hiroyuki
H
Satake
From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Michinori
M
Hirano
From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Hiroaki
H
Shimokawa
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D009202:Cardiomyopathies / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D012507:Sarcoidosis / Q000188:drug therapy*; D017180:Tachycardia, Ventricular / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000453:epidemiology; D013997:Time Factors
D000305:Adrenal Cortex Hormones
inflammation; prevalence; risk factor; sarcoidosis; ventricular fibrillation